Suppr超能文献

相似文献

3
MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer.
Nat Commun. 2020 Jan 17;11(1):338. doi: 10.1038/s41467-019-14219-6.
4
Identification of Novel Diagnosis Biomarkers for Therapy-Related Neuroendocrine Prostate Cancer.
Pathol Oncol Res. 2021 Sep 27;27:1609968. doi: 10.3389/pore.2021.1609968. eCollection 2021.
7
Regulation of CEACAM5 and Therapeutic Efficacy of an Anti-CEACAM5-SN38 Antibody-drug Conjugate in Neuroendocrine Prostate Cancer.
Clin Cancer Res. 2021 Feb 1;27(3):759-774. doi: 10.1158/1078-0432.CCR-20-3396. Epub 2020 Nov 16.
10
A novel mechanism of SRRM4 in promoting neuroendocrine prostate cancer development via a pluripotency gene network.
EBioMedicine. 2018 Sep;35:167-177. doi: 10.1016/j.ebiom.2018.08.011. Epub 2018 Aug 10.

引用本文的文献

1
New Insights into Potential Therapeutic Targets for Neuroendocrine Prostate Cancer: From Bench to Clinic.
Research (Wash D C). 2025 Jul 31;8:0791. doi: 10.34133/research.0791. eCollection 2025.
3
The role of transcription factors in prostate cancer progression.
Mol Cells. 2025 Apr;48(4):100193. doi: 10.1016/j.mocell.2025.100193. Epub 2025 Feb 10.
4
Investigating POU3F4 in cancer: Expression patterns, prognostic implications, and functional roles in tumor immunity.
Heliyon. 2024 Dec 31;11(1):e41587. doi: 10.1016/j.heliyon.2024.e41587. eCollection 2025 Jan 15.
6
The neuroendocrine transition in prostate cancer is dynamic and dependent on ASCL1.
Nat Cancer. 2024 Nov;5(11):1641-1659. doi: 10.1038/s43018-024-00838-6. Epub 2024 Oct 11.
7
The biological function of extracellular vesicles in prostate cancer and their clinical application as diagnostic and prognostic biomarkers.
Cancer Metastasis Rev. 2024 Dec;43(4):1611-1627. doi: 10.1007/s10555-024-10210-w. Epub 2024 Sep 24.
9
SYT4 binds to SNAP25 to facilitate exosomal secretion and prostate cancer enzalutamide resistance.
Cancer Sci. 2024 Aug;115(8):2630-2645. doi: 10.1111/cas.16239. Epub 2024 Jun 18.
10
Liquid biopsy to personalize treatment for metastatic prostate cancer.
Am J Transl Res. 2024 May 15;16(5):1531-1549. doi: 10.62347/DICU9510. eCollection 2024.

本文引用的文献

1
Targeting DLL3 in neuroendocrine prostate cancer.
Nat Rev Urol. 2019 Jun;16(6):330. doi: 10.1038/s41585-019-0190-6.
2
Salinomycin triggers endoplasmic reticulum stress through ATP2A3 upregulation in PC-3 cells.
BMC Cancer. 2019 Apr 25;19(1):381. doi: 10.1186/s12885-019-5590-8.
3
Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer.
Sci Transl Med. 2019 Mar 20;11(484). doi: 10.1126/scitranslmed.aav0891.
4
Cancer statistics, 2019.
CA Cancer J Clin. 2019 Jan;69(1):7-34. doi: 10.3322/caac.21551. Epub 2019 Jan 8.
5
ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axis.
Nat Med. 2018 Dec;24(12):1887-1898. doi: 10.1038/s41591-018-0241-1. Epub 2018 Nov 26.
8
microRNA-1246 Is an Exosomal Biomarker for Aggressive Prostate Cancer.
Cancer Res. 2018 Apr 1;78(7):1833-1844. doi: 10.1158/0008-5472.CAN-17-2069. Epub 2018 Feb 1.
9
Molecular Mechanisms of Enzalutamide Resistance in Prostate Cancer.
Curr Mol Biol Rep. 2017;3(4):230-235. doi: 10.1007/s40610-017-0079-1. Epub 2017 Oct 23.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验